(Q43522608)

English

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thomas Bachelot

1

object named as

Thomas Bachelot

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Gilles Romieu

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Mario Campone

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Véronique Diéras

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Claire Cropet

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Florence Dalenc

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Marta Jimenez

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Emilie Le Rhun

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Jean-Yves Pierga

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Anthony Gonçalves

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Marianne Leheurteur

11

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Julien Domont

12

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Maya Gutierrez

13

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hervé Curé

14

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Jean-Marc Ferrero

15

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Catherine Labbe-Devilliers

16

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

2 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

64-71

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in CSF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain metastases: the HER2 paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CNS metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating non-randomised intervention studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970432-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70432-1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43522608&oldid=2098078889"